Outsourcing

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Legislation has hampered cross-border drug importation and limited choice.

Q&A with Magnetrol International's Dan Klees

Food-safety, transparency, and counterfeit-drug growth will tax agency resources.

More crucial biomanufacturing operations are expected to be outsourced.

Anticounterfeiting solutions for vials and syringes.

As the industry prepares for Informex, the trade show of custom and batch manufacturers in Charlotte, North Carolina, a roundup of key recent developments.

Innovations protect the quality of temperature-sensitive products.

The authors highlight the need for a technology-transfer process that is efficient, cost-effective, and repeatable, stressing the importance of process understanding. Read this and other preferred organization articles in this special issue.

The article examines pharmaceutical market growth, company positioning, and the innovation potential in emerging markets. Read this and other preferred organization articles in this special issue.

A contract-service provider roundtable, featuring Albemarle, Baxter, DPT, Pfizer CentreSource, Dr. Reddy's, SAFC, and Vetter. Read this and other preferred organization articles in this special issue.

The designation of preferred partners has become integral to the outsourcing process. Read this and other preferred organization articles in this special issue.

The author analyzes the results of a survey that polled pharmaceutical executives and managers about both sides of the outsourcing relationship. Read this and other preferred organization articles in this special issue.

Pharmaceutical-industry executives from Merck & Co., Pfizer, and Covidien share their perspectives on their expectations and evaluation in the preferred-provider relationship. Read this and other preferred organization articles in this special issue.

Novartis Acquires Genoptix; Lilly Exec Becomes Savient CEO; and More.

Reflecting the manufacturing restructuring ongoing in the bio/pharmaceutical industry, Amgen and sanofi-aventis announced the sale of manufacturing facilities to contract manufacturers.

Merck Teams with Parexel; Roche CFO to Retire; and More

Gilead Sciences to Acquire Arresto Biosciences; Sartorius Appoints Head of Lab Business; and More.

Contract manufacturers strengthen their toolboxes and partnerships as they navigate the changing drug-development model.

The European Commission and Medicines Agency seem to be moving in advance of their ICH partners to update standards.

Expert and implementation working groups harmonize more guidelines and move Q11 forward.

Industry executives share insight into the future direction of drug manufacturing and the supply chain. This article contains online bonus material.

Top priorities for manufacturers include user fees, new health initiatives, and regulatory compliance.

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.

A Q&A with Spectrum Laboratories President Tony MacDonald.

Holding product and supply-chain security to the highest standards is crucial for the future.

Industry experts offer their best practices for dealing with deviations. This article contains online bonus material.

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

AstraZeneca and Abbott End Program; PhRMA Elects New Members; and More.

After five years of discussions, the US Food and Drug Administration is joining the Pharmaceutical Inspection Convention (PIC) and the Pharmaceutical Inspection Cooperation Scheme (PIC Scheme), known together as PIC/S.